Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors

Authors: Ivy A Ho, Wai H Ng, Paula Y Lam

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Glioblastoma multiforme is the most malignant cancer of the brain and is notoriously difficult to treat due to the highly proliferative and infiltrative nature of the cells. Herein, we explored the combination treatment of pre-established human glioma xenograft using multiple therapeutic genes whereby the gene expression is regulated by both cell-type and cell cycle-dependent transcriptional regulatory mechanism conferred by recombinant HSV-1 amplicon vectors.

Results

We demonstrated for the first time that Ki67-positive proliferating primary human glioma cells cultured from biopsy samples were effectively induced into cell death by the dual-specific function of the pG8-FasL amplicon vectors. These vectors were relatively stable and exhibited minimal cytotoxicity in vivo. Intracranial implantation of pre-transduced glioma cells resulted in better survival outcome when compared with viral vectors inoculated one week post-implantation of tumor cells, indicating that therapeutic efficacy is dependent on the viral spread and mode of viral vectors administration. We further showed that pG8-FasL amplicon vectors are functional in the presence of commonly used treatment regimens for human brain cancer. In fact, the combined therapies of pG8-FasL and pG8-FADD in the presence of temozolomide significantly improved the survival of mice bearing intracranial high-grade gliomas.

Conclusion

Taken together, our results showed that the glioma-specific and cell cycle-dependent HSV-1 amplicon vector is potentially useful as an adjuvant therapy to complement the current gene therapy strategy for gliomas.
Appendix
Available only for authorised users
Literature
1.
2.
Kumar HR, Zhong X, Sandoval JA, Hickey RJ, Malkas LH: Applications of emerging molecular technologies in glioblastoma multiforme. Expert Rev Neurother. 2008, 8: 1497-1506. 10.1586/14737175.8.10.1497PubMedCentralCrossRefPubMed
3.
Rao JS: Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003, 3: 489-501. 10.1038/nrc1121CrossRefPubMed
4.
Ho IA, Hui KM, Lam PY: Glioma-specific and cell cycle-regulated herpes simplex virus type 1 amplicon viral vector. Hum Gene Ther. 2004, 15: 495-508. 10.1089/10430340460745810CrossRefPubMed
5.
Wang GY, Ho IA, Sia KC, Miao L, Hui KM, Lam PY: Engineering an improved cell cycle-regulatable herpes simplex virus type 1 amplicon vector with enhanced transgene expression in proliferating cells yet attenuated activities in resting cells. Hum Gene Ther. 2007, 18: 222-231. 10.1089/hum.2006.140CrossRefPubMed
6.
Ho IA, Hui KM, Lam PY: Targeting proliferating tumor cells via the transcriptional control of therapeutic genes. Cancer Gene Ther. 2006, 13: 44-52. 10.1038/sj.cgt.7700864CrossRefPubMed
7.
Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science. 1998, 281: 1305-1308. 10.1126/science.281.5381.1305CrossRefPubMed
8.
Thorburn A: Death receptor-induced cell killing. Cell Signal. 2004, 16: 139-144. 10.1016/j.cellsig.2003.08.007CrossRefPubMed
9.
Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D: A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem. 1995, 270: 7795-7798. 10.1074/jbc.270.14.7795CrossRefPubMed
10.
Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H: Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res. 1995, 55: 5528-5530.PubMed
11.
Husain N, Chiocca EA, Rainov N, Louis DN, Zervas NT: Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol. 1998, 95: 287-290. 10.1007/s004010050799CrossRefPubMed
12.
Strege RJ, Godt C, Stark AM, Hugo HH, Mehdorn HM: Protein expression of Fas, Fas ligand, Bcl-2 and TGFbeta2 and correlation with survival in initial and recurrent human gliomas. J Neurooncol. 2004, 67: 29-39. 10.1023/B:NEON.0000021739.34343.75CrossRefPubMed
13.
Hahne M, Renno T, Schroeter M, Irmler M, French L, Bornard T, MacDonald HR, Tschopp J: Activated B cells express functional Fas ligand. Eur J Immunol. 1996, 26: 721-724. 10.1002/eji.1830260332CrossRefPubMed
14.
15.
Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L, Stringaro A, Molinari A, Arancia G, Gentile M, Parmiani G, Fais S: Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med. 2002, 195: 1303-1316. 10.1084/jem.20011624PubMedCentralCrossRefPubMed
16.
Weller M, Kleihues P, Dichgans J, Ohgaki H: CD95 ligand: lethal weapon against malignant glioma?. Brain Pathol. 1998, 8: 285-293. 10.1111/j.1750-3639.1998.tb00154.xCrossRefPubMed
17.
Riffkin CD, Gray AZ, Hawkins CJ, Chow CW, Ashley DM: Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction. Neuro Oncol. 2001, 3: 229-240.PubMedCentralPubMed
18.
Karlsson T, Henriksson R, Hedman H: Induction of apoptosis in resistant glioma cells by synthetic caspase-activation. J Neurooncol. 2004, 66: 71-79. 10.1023/B:NEON.0000013485.09953.25CrossRefPubMed
19.
Kondo S, Ishizaka Y, Okada T, Kondo Y, Hitomi M, Tanaka Y, Haqqi T, Barnett GH, Barna BP: FADD gene therapy for malignant gliomas in vitro and in vivo. Hum Gene Ther. 1998, 9: 1599-1608. 10.1089/hum.1998.9.11-1599CrossRefPubMed
20.
Ashley DM, Riffkin CD, Muscat AM, Knight MJ, Kaye AH, Novak U, Hawkins CJ: Caspase 8 is absent or low in many ex vivo gliomas. Cancer. 2005, 104: 1487-1496. 10.1002/cncr.21323CrossRefPubMed
21.
Merlo A: Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev. 2003, 26: 145-158.PubMed
22.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum Gene Ther. 2002, 13: 1015-1025. 10.1089/104303402753812421CrossRef
23.
Chan DY, Chen GG, Poon WS, Liu PC: Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis. J Neurooncol. 2008, 86: 273-283. 10.1007/s11060-007-9475-3PubMedCentralCrossRefPubMed
24.
Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997, 23: 35-61. 10.1016/S0305-7372(97)90019-0CrossRefPubMed
25.
Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M: Current Therapeutic Paradigms in Glioblastoma. Rev Recent Clin Trials. 2010, 5: 14-27. 10.2174/157488710790820544CrossRefPubMed
26.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352: 987-996. 10.1056/NEJMoa043330CrossRefPubMed
27.
Hirose Y, Berger MS, Pieper RO: p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001, 61: 1957-1963.PubMed
28.
Wilson CB: Glioblastoma: the past, the present, and the future. Clin Neurosurg. 1992, 38: 32-48.PubMed
29.
Corsini NS, Sancho-Martinez I, Laudenklos S, Glagow D, Kumar S, Letellier E, Koch P, Teodorczyk M, Kleber S, Klussmann S, Wiestler B, Brustle O, Mueller W, Gieffers C, Hill O, Thiemann M, Seedorf M, Gretz N, Sprengel R, Celikel T, Martin-Villalba A: The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell. 2009, 5: 178-190. 10.1016/j.stem.2009.05.004CrossRefPubMed
30.
Didenko VV, Ngo HN, Minchew C, Baskin DS: Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J Neurosurg. 2002, 96: 580-584. 10.3171/jns.2002.96.3.0580PubMedCentralCrossRefPubMed
31.
Yu JS, Lee PK, Ehtesham M, Samoto K, Black KL, Wheeler CJ: Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium. J Neurooncol. 2003, 64: 55-61.PubMed
32.
Nafe C, Cao YJ, Quinones A, Dobberstein KU, Kramm CM, Rainov NG: Expression of mutant non-cleavable Fas ligand on retrovirus packaging cells causes apoptosis of immunocompetent cells and improves prodrug activation gene therapy in a malignant glioma model. Life Sci. 2003, 73: 1847-1860. 10.1016/S0024-3205(03)00542-3CrossRefPubMed
33.
Rubinchik S, Yu H, Woraratanadharm J, Voelkel-Johnson C, Norris JS, Dong JY: Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther. 2003, 10: 814-822. 10.1038/sj.cgt.7700651CrossRefPubMed
34.
Muruve DA, Nicolson AG, Manfro RC, Strom TB, Sukhatme VP, Libermann TA: Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after Systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Hum Gene Ther. 1997, 8: 955-963. 10.1089/hum.1997.8.8-955CrossRefPubMed
35.
Sonabend AM, Ulasov IV, Lesniak MS: Gene therapy trials for the treatment of high-grade gliomas. Gene Ther Mol Biol. 2007, 11: 79-92.PubMedCentralPubMed
36.
Rueger MA, Winkeler A, Miletic H, Kaestle C, Richter R, Schneider G, Hilker R, Heneka MT, Ernestus RI, Hampl JA, Fraefel C, Jacobs AH: Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther. 2005, 12: 588-596. 10.1038/sj.gt.3302462CrossRefPubMed
37.
Chen J, Bezdek T, Chang J, Kherzai AW, Willingham T, Azzara M, Nisen PD: A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res. 1998, 58: 3504-3507.PubMed
38.
Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest. 1994, 94: 954-964. 10.1172/JCI117462PubMedCentralCrossRefPubMed
39.
Bertrand J, Begaud-Grimaud G, Bessette B, Verdier M, Battu S, Jauberteau MO: Cancer stem cells from human glioma cell line are resistant to Fas-induced apoptosis. Int J Oncol. 2009, 34: 717-727.PubMed
40.
Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006, 5: 67- 10.1186/1476-4598-5-67PubMedCentralCrossRefPubMed
41.
Nagane M, Cavenee WK, Shiokawa Y: Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg. 2007, 106: 407-416. 10.3171/jns.2007.106.3.407CrossRefPubMed
42.
Suzuki M, Chiocca EA, Saeki Y: Stable transgene expression from HSV amplicon vectors in the brain: potential involvement of immunoregulatory signals. Mol Ther. 2008, 16: 1727-1736. 10.1038/mt.2008.175CrossRefPubMed
43.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10: 459-466. 10.1016/S1470-2045(09)70025-7CrossRefPubMed
44.
Yamini B, Yu X, Pytel P, Galanopoulos N, Rawlani V, Veerapong J, Bickenbach K, Weichselbaum RR: Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. Clin Cancer Res. 2007, 13: 6217-6223. 10.1158/1078-0432.CCR-07-1421CrossRefPubMed
45.
Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M: O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 2006, 96: 766-776. 10.1111/j.1471-4159.2005.03583.xCrossRefPubMed
46.
Kato T, Natsume A, Toda H, Iwamizu H, Sugita T, Hachisu R, Watanabe R, Yuki K, Motomura K, Bankiewicz K, Wakabayashi T: Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 2010, advance online publication,
47.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005, 352: 997-1003. 10.1056/NEJMoa043331CrossRefPubMed
48.
Shariat SF, Desai S, Song W, Khan T, Zhao J, Nguyen C, Foster BA, Greenberg N, Spencer DM, Slawin KM: Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer. Cancer Res. 2001, 61: 2562-2571.PubMed
49.
Tsurushima H, Yuan X, Dillehay LE, Leong KW: Radiation-inducible caspase-8 gene therapy for malignant brain tumors. Int J Radiat Oncol Biol Phys. 2008, 71: 517-525.CrossRefPubMed
50.
Shimamura T, Husain SR, Puri RK: The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. Neurosurg Focus. 2006, 20: E11- 10.3171/foc.2006.20.4.6CrossRefPubMed
51.
Mueller LP, Luetzkendorf J, Mueller T, Reichelt K, Simon H, Schmoll HJ: Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem Cells. 2006, 24: 2753-2765. 10.1634/stemcells.2006-0108CrossRefPubMed
52.
Chen MF, Lin CT, Chen WC, Yang CT, Chen CC, Liao SK, Liu JM, Lu CH, Lee KD: The sensitivity of human mesenchymal stem cells to ionizing radiation. Int J Radiat Oncol Biol Phys. 2006, 66: 244-253.CrossRefPubMed
53.
Eichler AF, Plotkin SR: Brain metastases. Curr Treat Options Neurol. 2008, 10: 308-314. 10.1007/s11940-008-0033-xCrossRefPubMed
54.
Ho IA, Chan KY, Miao L, Shim WS, Guo CM, Cheang P, Hui KM, Lam PY: HSV-1 amplicon viral vector-mediated gene transfer to human bone marrow-derived mesenchymal stem cells. Cancer Gene Ther. 2008, 15: 553-562. 10.1038/cgt.2008.27CrossRefPubMed
55.
Saeki Y, Breakefield XO, Chiocca EA: Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med. 2003, 76: 51-60.PubMed
56.
Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS: Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer. 2009, 100: 1154-1164. 10.1038/sj.bjc.6604969PubMedCentralCrossRefPubMed
57.
Hirt B: Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol. 1967, 26: 365-369. 10.1016/0022-2836(67)90307-5CrossRefPubMed
Metadata
Title
FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors
Authors
Ivy A Ho
Wai H Ng
Paula Y Lam
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-270

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers

Research

VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A

Research

Integrative analysis of DNA copy number and gene expression in metastatic oral squamous cell carcinoma identifies genes associated with poor survival

Research

Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors

Research

HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling

Research

The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits